
Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.
Click the title above to open the BioPharm International February 2016 issue in an interactive PDF format.
almost 11 years ago
Antibody Production in Microbial Hostsalmost 11 years ago
Advances in Assay Technologies for CAR T-Cell Therapiesalmost 11 years ago
Innovative Therapies Require Modern Manufacturing Systemsalmost 11 years ago
Macro Mattersalmost 11 years ago
Fine Tuning the Focus on Biopharma Analytical Studiesalmost 11 years ago
Biopharma Innovation Born Again?almost 11 years ago
Failure Mode Effects Analysis for Filter Integrity Testingalmost 11 years ago
The Emerging View of Endotoxin as an IIRMIalmost 11 years ago
Use of an E. coli pgi Knockout Strain as a Plasmid Producer





